Recurrent vulvovaginal candidiasis (RVVC) infection is an under-appreciated, under-reported, and under-served women’s health condition. RVVC, defined as three or more episodes of vulvovaginal candidiasis infection in one year, affects approximately 5%-8% of women during their childbearing years.
RVVC results in considerable suffering, costs, and interference with sexual satisfaction. Health-related quality of life is negatively influenced by RVVC, according to an online survey conducted in 620 women experiencing RVVC in Europe and the United States*.
*In an online survey conducted in 620 women experiencing RVVC in Europe and the United States, SF-36 questionnaire was used for HRQoL assessment.
women worldwide experience RVVC annually1
women in the United States suffer from RVVC1
References: 1. Denning DW, et al. Lancet Infect Dis. 2018;18(11):e339-e347. doi:10.1016/S1473-3099(18)30103-8. 2. Johnson SR, Griffiths H, Humberstone FJ et al. Attitudes and experience of women to common vaginal infections… VVC: Vulvovaginal Candidias
In addition, antifungal resistance has become a serious problem for some patients diagnosed with a vaginal yeast infection, resulting in recurring infections and infections that are never completely resolved. Evidence suggests that broad and frequent use of azoles, which are fungistatic and inhibit the growth of yeast, may be contributing to the increase in non-albicans Candida, and fluconazole-resistant Candida species.
SCYNEXIS conducted a Phase 3 clinical trial (CANDLE) to investigate ibrexafungerp, which is fungicidal, as a possible therapy to prevent recurring infections.